Marine Polymer Technologies, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Novartis Ag

The Brigham and Women's Hospital, Inc.

Marine Polymers Technologies

The United States of America as Represented by the Secretary of

Musc Foundation for Research Development

Admune Therapeutics LLC

John N Vournakis

Sergio Finkielsztein

Ernest R Pariser

Mike Helton

George N Pavlakis

Barbara K Felber

Dennis Paul Orgill

Marco Finkielsztein

George A Gaitanaris

Giorgio Pietramaggiori

Roland H Stauber

Takis S Papas

Sergio Finkielstein

Arun K Seth

This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof ('sNAG nanofibers') and the use of such compositions in the treatment of disease.

Treatment of disease with poly-N-acetylglucosamine nanofibers

Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof ('sNAG nanofibers') and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.

Anti-bacterial applications of poly-N-acetylglucosamine nanofibers

The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.

Hemostatic compositions and therapeutic regimens

Described herein are dose escalation regimens for the administration of complexes comprising interleukin-15 ('IL-15') covalently or noncovalently bound to IL-15 receptor alpha ('IL-15R&#x3b1;') to patients in order to enhance IL-15-mediated immune function. In a specific aspect, the dose escalation regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficiencies and lymphopenia. In another specific aspect, the dose escalation regimens are useful for eradicating or reducing HIV in HIV-infected patients.

IL-15 and IL-15R&#x3b1; heterodimer dose escalation regimens for treating conditions

This invention relates in general to a method and device for facilitating hemostasis and wound healing. In particular, the invention relates to the device comprising a polymeric material disposed on a scaffold that facilitates hemostasis and wound healing. Specifically, the invention contemplates the use of such scaffolds in conjunction with a negative pressure device.

Application of polymeric materials to screens to facilitate hemostasis and wound healing

A vascular compression apparatus and method for applying pressure onto an area of a patient generally including a blood vessel and a wound site, such as a blood vessel puncture, after a cannulated procedure for the purpose of controlling bleeding and achieving hemostasis. The vascular compression apparatus includes a handle, a shaft and a pad. The shaft extends generally downward from the center of the bottom side of the handle. The pad is connected generally off-center of its top side to the bottom end of the shaft. The bottom side of the pad is convex to allow the vascular compression device to be rocked back and forth. In use, the pad is generally placed proximal to the catheter insertion site and over the blood vessel containing the catheter. The device is rocked proximally to control blood flow while removing the catheter. After the catheter is removed from the puncture site, the device is rocked distally to the puncture site, where pressure is applied until hemostasis is achieved.

Methods and apparatus for a manual vascular compression device

The present invention relates to agents that modulate interleukin-15 ('IL-15') signal transduction or function ('Therapeutic Agents') and the use ol&#x2033; those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-&#x3b2;-1-&#x2666;4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.

Cell expressing complexes of IL-15 and IL-15Ralpha

The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to achieve hemostasis at an increased rate. More specifically the present invention relates to hemostatic compositions that achieve a hemostatic effect at a distance from the site of application of the composition, and a method for administering such a composition to effectively reduce localized vascular complications associated with treating a breach or puncture in a vein or artery and reduce the time to achieve hemostasis.

Hemostatic compositions and uses therefor

The present invention relates generally to the field of hemodialysis, including methods and kits that can be employed to improve hemodialysis therapy. The present invention encompasses methods and kits useful for reducing vascular access complications associated with hemodialysis therapy and prolonging the period of time for which a vascular access site can be used in a patient.

Growing community of inventors

Hanover, NH, United States of America

John N Vournakis